Exicure, Inc. (XCUR) stock
Close on Nov 13, 2026Market cap $7.07MP/E –Yield –
Exicure, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026. Free cash flow was -$8.56M. At the latest close the market valued the company at $7.07M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $7.07M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 7.24
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$8.28M
- EPS, diluted
- -$1.31
- Free cash flow
- -$8.56M
- Book value per share
- $0.15
- Diluted shares
- 6M
Trading
- Previous close
- $1.06
- Open
- $1.01
- Day's range
- $1.01 – $1.08
- Volume
- 7,905
- Average volume (20 days)
- 99,068
- Beta (5 years)
- 1.25
- 52-week range
- $0.78 – $9.48
- RSI (14 days)
- 51.5
- Volatility (1 year)
- 111.6%
- Relative volume
- 0.03×
- WACC
- 11.3%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | XCUR | S&P 500 | Difference | XCUR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.1% | -3.0% | −3.0 pts | ||
| 3 months | -17.6% | -2.8% | −14.8 pts | ||
| Year to date | -80.1% | +11.5% | −91.6 pts | ||
| 1 year | -70.4% | +13.5% | −83.9 pts | ||
| 3 years | -63.3% | +77.7% | −141.0 pts | -28.4% | +21.1% |
| 5 years | -99.3% | +72.6% | −172.0 pts | -63.4% | +11.5% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Exicure filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- News
- News
- Results
About Exicure
Pharmaceutical Preparations
Exicure, Inc. is a clinical-stage biotechnology company focused on developing therapies based on licensed intellectual property and proprietary technologies. Through its acquired subsidiary, GPCR Therapeutics USA Inc., the company concentrates on therapeutic candidates for oncology, specifically targeting blood cancers such as multiple myeloma. Its primary clinical trial program evaluates the combined administration of the chemokine receptor antagonist GPC-100 with propranolol to mobilize stem cells for patients eligible for bone marrow transplantation. The company has historically explored broader strategic alternatives, acquisitions, and collaborations across the biotechnology sector.
Company profile, executives and historyExicure stock: common questions
What is Exicure's stock price?
XCUR closed at $1.08 on Nov 13, 2026, up 1.89% on the day. Over the past 52 weeks it traded between $0.78 and $9.48.
What is Exicure's market cap?
Exicure was worth $7.07M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is XCUR's P/E ratio?
Exicure lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.31), so it has no meaningful P/E ratio.
How much revenue does Exicure make?
Exicure reported revenue of $0 for the twelve months to Jun 30, 2026.
Does Exicure pay a dividend?
No. Exicure has not paid a cash dividend over the last twelve months.
How has XCUR stock performed over the past year?
Including dividends, XCUR returned -70.4% over the past year, against +13.5% for the S&P 500.
How many XCUR shares are sold short?
0M shares were sold short at the latest FINRA report, 10.81% of the float, or 1.0 days of average trading volume.
Who are Exicure's competitors?
Companies most similar to Exicure by business, industry and size include SCNX, ERNA, LIPO, VCNX, RLYB.
See a number that looks wrong?